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Interleukin-17 (IL-17) is a pro-inflammatory cytokine that is mainly produced by CD4 + T cells. The role of Th17
during the human immunodeficiency virus (HIV)-1 infection is still unclear, but HIV-1 infection can cause a
preferential depletion of Th17 cells. It has been shown that IL-15 elicits IL-17 production from human peripheral
blood mononuclear cells. We studied the effect of IL-15 stimulation in vitro on IL-17 production from CD4 +
mononuclear cells of HIV-infected patients. We observed that IL-15 triggers, in a dose-dependent manner, IL-17
secretion. This effect was blocked by anti-IL-15 monoclonal antibody (P = 0.01). Interestingly, IL-17 production
was significantly lower in patients with detectable plasma viremia when compared with successfully treated
HIV-infected patients (P= 0.02) and healthy controls, respectively (P < 0.001). We also noticed a significant dif-
ference in IL-17 production between naı¨ve HIV-infected patients and patients with virological failure on com-
bined antiretroviral therapy (cART) (P = 0.02). Our results suggest that IL-15 can induce IL-17 production from
peripheral CD4 + mononuclear cells of HIV-infected patients. Persistent HIV plasma viremia could cause a
severe perturbation of IL-17 production from CD4 + mononuclear cells. IL-17 production in HIV-infected pa-
tients could be recovered through a sustained suppression of the viral replication in the peripheral blood
through cART.
Introduction
Interleukin-17 (IL-17) is a pro-inflammatory cytokinethat is mainly produced by a new class of effector CD4+ T
lymphocytes (Harrington and others 2005). Th17 lympho-
cytes constitute a recently characterized subset of T-helper
cells that are characterized by the secretion of a distinct
pattern of cytokines: IL-17A, IL-17F, IL-21, IL-22, and IL-26
(Wilson and others 2007).
Th17 lymphocytes are involved in the induction of a
protective immune response against a variety of bacteria
and fungi, including human immunodeficiency virus (HIV)-
associated opportunistic pathogens. The ability to indirectly
induce the recruitment of neutrophils highlights the role of
the Th17 cells as a linking bridge between innate and
adaptive immune response (Matsuzaki and Umemura 2007;
Rudner and others 2007; Pelletier and others 2010; Gaffen
and others 2011). The clinical importance of the Th17 cells
has been clearly described in Hyper-IgE syndrome (HIES)
(Milner and others 2008). This rare primary immune defi-
ciency is characterized by: mutations in the gene encoding
STAT3, decreased number of Th17 lymphocytes, and, sub-
sequently, a low level of IL-17. Patients affected by HIES
suffer from frequent bacterial and fungal infections, as seen
during the HIV-1 infection (Freeman and Holland 2010).
IL-1b, IL-23, transforming growth factor-beta (TGF-b), and
IL-6 are considered key factors for the development and the
proliferation of Th17 cells (Acosta-Rodriguez and others
2007; Volpe and others 2008).
Recently, a new strong relationship between Th17 and IL-
15 has been demonstrated in several autoimmune diseases
such as rheumatoid arthritis and psoriasis (Ziolkowska and
others 2000; Elder 2007; Hot and Miossec 2011). Moreover,
IL-15 induces the strongest production of IL-17 from human
peripheral blood mononuclear cells (PBMCs) when com-
pared with IL-2 and IL-23 (Hoeve and others 2006).
Our group is particularly interested in the effect of IL15 on
the immune cells during HIV infection. IL-15 is a pleiotropic
cytokine with a broad range of biological functions in many
diverse cell types that plays a pivotal role in the modulation
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of immune cells of both the innate and adaptive immune
systems and in the inflammatory and protective immune
responses. From a molecular point of view, IL-15 is a 14–
15 kDa glycoprotein that is encoded by a 34 kb region on
human chromosome 4q31. Its receptor is composed of a b
subunit (IL-2R/15Rb) that is shared with the IL-2 receptor, a
common g subunit (gc) shared with IL-2, IL-4, IL-7, IL-9, and
IL-21, and a unique a subunit (IL-15Ra) which confers re-
ceptor specificity to IL-15 (Steel and others 2012). IL-15
mRNA is expressed by multiple tissues (skeletal muscle,
kidney, lung, heart, and placenta) and numerous cell types
through various stimulatory conditions, including fibro-
blasts, keratinocytes, epithelial cells of various tissues, nerve
cells, monocytes, macrophages, T cells, and dendritic cells
(DCs) (Anderson and others 1995; Waldmann and Tagaya
1999; Steel and others 2012). Although IL-15 mRNA ex-
pression is widespread, detection of IL-15 protein is largely
limited to DCs and monocytes/macrophages. This indicates
that, although transcriptional control of IL-15 is important
(transcription, translation, and intracellular trafficking
stages), the principle level of IL-15 regulation appears to be
posttranscriptional. IL-15 protein is post-transcriptionally
regulated by multiple controlling elements that impede
translation, including 12 upstream adenine, uracil, guanine
of the 5¢ untranslated region, 2 unusual signal peptides, and
the C-terminus of the mature protein (Fehniger and Caligiuri
2001). Finally, a large variety of stimuli induce IL-15 ex-
pression and/or release, including lipopolysaccharide and
other bacterial products, fungi, viruses, and double-stranded
RNA (D’Acquisto and others 2010). From a functional point
of view, IL-15 is to act on several immune cells as CD4+ T
cells, CD8+ T and NK cells inducing the expansion as well
as the production of different cytokines and chemokines. We
have already demonstrated the potential role of IL-15 in
enhancing the NK cells response against HIV-1 infection
in vitro (d’Ettorre and others 2006, 2011).
In the present article, we evaluated the effect of the IL-15
stimulation in vitro on the secretion of IL-17 from human
CD4+ mononuclear cells isolated from HIV-infected patients
with distinct clinical and virological characteristics.
Patients and Methods
Study participants included a total of 15 HIV-infected
patients and 5 healthy controls from the Department of
Public Health and Infectious Diseases of Sapienza University
of Rome. Five HIV-infected patients were naive for anti-
retroviral drugs and presented median CD4+ cell count of
689 cells/mm3 (range 501–1,076 cells/mm3) and median
viral load (VL) of 3,514 HIV RNA copies/mL (range
52–17,000 cp/mL); five HIV-infected patients treated with
combined anti retroviral therapy (cART) presented sustained
viral suppression (< 50 copies/mL) and median CD4+ cell
count of 700 cells/mm3 (range 314–1,164 cells/mm3) at the
time of the blood draw (cART success). Five HIV-infected
patients considered cART failures, presented a median
CD4+ count of 325 cells/mm3 (range 179–654 cells/mm3)
and median plasma VL of 3,000 HIV RNA copies/mL (range
189–4,159 cp/mL). All the patients had received a combina-
tion of protease inhibitors or a non-nucleoside reverse tran-
scriptase inhibitor with 2 nucleoside or nucleotide reverse
transcriptase inhibitors for 48–184 weeks. No evidence of
active opportunistic infections was found at the time of
blood sample handling. All individuals signed informed
consents approved by the Institutional Review Board of
University of Rome ‘‘Sapienza,’’ Rome, Italy.
PBMCs from blood of HIV-uninfected and HIV-infected
subjects were prepared using Hypaque–Ficoll density centri-
fugation (Accuprep). CD4+ mononuclear cells were isolated
staining PBMCs with biotinylated anti-CD8 followed by
avidin-coated magnetic beads and purified over an MACS
column (Miltenyi Biotech), following the manufacturer’s
instructions. Cell purity was > 95% + , as measured by flow
cytometry. Freshly isolated CD4+ mononuclear cells (5· 105/
mL)were cultured in 24-well plates in Roswell ParkMemorial
Institute (culture medium) 1640 supplemented with 2mM
l-glutamine, 10% fetal calf serum (Seromed), 100U/mL
penicillin, 100mg/mL streptomycin, and 1mM hydroxyethyl-
piperazine ethanesulafonic acid at 37C in an atmosphere of
95% air and 5% CO2. Cells were stimulated for 72 h in the
presence or absence of a mixture of phorbol myristate acetate
(1 nM) and ionomycin (3 mg/mL), or cytokine: IL-15 (0,
1–100 ng/mL; Immunex). To study the effect of neutralizing
anti-IL-15 monoclonal antibody (mAb) on IL-15-induced
production of IL-17, recombinant human IL-15 (100 ng) was
incubated with or without anti-IL-15 mAb (M111, 3mg) or
normal mouse mAb (3mg) for 30min at 37C before addition
to cell cultures. After incubation, culture supernatants were
collected by centrifugation at 400g for 10min, and concen-
trations of IL-17were determined using human IL-17 enzyme-
linked immunosorbent assay (ELISA) kit (R&D System). The
lowest limit of detection was 15pg/mL for IL-17.
Moreover, with the aim of evaluating whether the in vivo
levels of both IL-15 and IL-17 were compromised in indi-
viduals with HIV infection, we determined the levels of these
cytokines in plasma samples from the study subjects. The
cytokine plasma levels were determined by ELISA method-
ology. In the same way, we evaluated the fraction of Th17
cells present among CD4 + T cells of each subject, by flow
cytometry.
Data are expressed as mean– standard error of the mean.
Statistical significance was evaluated using paired Student’s
t-test for the in vitro experiments. The concentrations of IL-17
released by CD4 + mononuclear cells were analyzed by non-
parametric Mann–Whitney Rank Sum test, using Graphpad
Prism 4 software (Graphpad Software Inc.). Probability
values < 0.05 were considered statistically significant.
Results
We stimulated freshly isolated CD4 + mononuclear cells
from healthy subjects with an increasing concentration of IL-
15 in order to detect IL-17 production in vitro. The stimula-
tion in vitro with an increasing amount of IL-15 induced a
statistically significant and dose-dependent increase in the
production of IL-17 by CD4+ mononuclear cells. The addi-
tion of monoclonal anti-IL-15 antibody significantly reduced
the secretion of IL-17 from the CD4 + mononuclear cells
isolated from the healthy donors when stimulated with IL-15
50 and 100 ng/mL (P = 0.04 and 0.01, respectively; Fig. 1).
We then evaluated the effects of IL-15 stimulation in vitro
on IL-17 secretion from CD4 + mononuclear cells of
HIV-infected patients. We observed a significant difference
in IL-17 secretion in vitro from IL-15 stimulated CD4+
mononuclear cells of HIV-infected patients with detectable
VL when compared with IL15-stimulated CD4+ cells of
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HIV-infected subjects with undetectable VL (P= 0.02) and
healthy controls (P< 0.001), respectively (data not shown). To
study the effect of HIV infection on IL-17 production, we
separated the HIV-infected patients on the basis of their
immunological and virological characteristics. We noticed a
statistically significant increased production of IL-17 from
CD4+ mononuclear cells of HIV-infected patients with
undetectable VL during cART when compared with HIV-
infected patients presenting virological failure in cART
(P= 0.02). Interestingly, IL-15 stimulated CD4+ mononuclear
cells of HIV-infected patients who were naı¨ve to anti-retroviral
treatment demonstrated a significant difference in IL-17 se-
cretion when compared with CD4+ cells from the patients
with virological failure (P= 0.02; Fig. 2). There was no signif-
icant difference in IL-17 secretion between CD4+ mononu-
clear cells from HIV-infected naı¨ve patients and HIV-infected
patients with undetectable VL during cART.
Plasma IL-15 levels (measured in vivo) were significantly
elevated in cART failure group (9.93– 2.64pg/mL) compared
with cART success group (5.65– 2.69pg/mL), naive subjects
(6.88– 1.97pg/mL), and healthy controls (3.62– 1.42pg/mL)
( p< 0.05). On the other hand, plasma IL-17 levels were sta-
tistically significantly lower in HIV patients with cART failure
(16.12– 0.26pg/mL) than those in patients with cART success
(26.88– 2.26pg/mL), in naive subjects (19.68– 1.25pg/mL),
and in healthy controls (31.24– 0.66pg/mL) ( p< 0.05). In the
same way also, the percentage of Th17 cells to total CD4+ T
cells was 1.6%– 0.37% in patients before treatment, which was
significantly lower than that in cART success group
(3.9%– 0.42%), in naı¨ve group (2.78%– 0.37%), and in unin-
fected controls (5.74%– 0.4%). Moreover, the percentage of
Th17 cells positively correlated with IL-17 levels (r= 0.98,
p= 0.001) (Table 1).
Discussion
The aim of this study was to investigate the potential effect
of IL-15 stimulation in vitro on the production of IL-17 by
CD4+ mononuclear cells of HIV-infected patients. We ini-
tially confirmed that IL-15 presents a dose-dependent effect
on IL-17 production from CD4 + cells of healthy donors. It
has been shown that IL-15 has the ability to expand a sub-
population of CD4+ T cells which are able to produce IL-17
(El Hed and others 2010). Moreover, IL-15 proved to strongly
induce IL-17 production by human T cells, especially when
compared with other cytokines such as IL-2 and IL-23
(Hoeve and others 2006). IL-15 enhances T-cell proliferation
and homeostasis through a variety of intracellular events in-
volving the activation of intracellular signaling molecules such
as Janus Kinase-3 and signal transducers and activators such
as STAT-5 and STAT-3 ( Johnston and others 1996; Giron-
Michel and others 2003). The latter nuclear transcription factor
is also critical for IL-6 and TGF-b-induced differentiation of
Th17 cells (Yang and others 2007). Thus, it is likely that IL-15
FIG. 1. The stimulation with IL-15 induces IL-17 produc-
tion from CD4+ mononuclear freshly isolated from human
PBMCs and is influenced by the HIV viremia. IL-17 con-
centrations in the supernatant fluids of freshly isolated hu-
man CD4+ mononuclear cells (5· 105/mL) incubated for
72 h with or without IL-15 (10mg/mL, 50 ng/mL, and
100 ng/mL) or anti-IL-15 mAb (M111, 3 ng/mL) in condi-
tioned medium and PMA/ionomycin. Stimulation with in-
creasing amounts of IL-15 triggers, in a dose-dependent
manner, IL-17 production from CD4+ mononuclear cells of
healthy controls (n = 5). The addition of anti-IL-15 monoclo-
nal antibody significantly reduces IL-17 production from
CD4 + T mononuclear cells previously stimulated with IL-15
(100 ng/mL). Medium contained no stimulus. Cytokine
concentrations in the conditioned medium were expressed in
pg/mL and were determined by ELISA. Data are expressed
as mean– standard error of the mean (SEM). Only significant
P values are shown. IL-17, interleukin-17; PBMCs, peripheral
blood mononuclear cells; HIV, human immunodeficiency
virus; anti-IL-15 mAb, anti-interleukin-IL-15 monoclonal
antibody; PMA, phorbol myristate acetate; ELISA, enzyme-
linked immunosorbent assay.
FIG. 2. IL-17 production from CD4 + mononuclear cells of
HIV-infected patients. IL-17 concentrations (pg/mL) were
compared among HIV-positive patients with virological
failure to cART (cART failures, n = 5), patients naive to cART
(cART naive, n = 5), patients with undetectable viral load
after cART (cART success, n = 5), and HIV-negative indi-
viduals (healthy controls, n = 5). IL-17 concentrations in su-
pernatant fluids of freshly isolated CD4 + mononuclear cells
(5· 105/mL) incubated for 72 h with IL-15 (50 ng/mL) in
conditioned medium. Cytokine level in the conditioned
medium is expressed in pg/mL and was determined by
ELISA. Data are expressed as mean– SEM. Only significant P
values are shown. cART, combined antiretroviral treatment.
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induces a dose-dependent IL-17 production from human
CD4+ mononuclear cells in a STAT-3-dependent manner.
The question whether IL-15 has direct effects in modulating
the synthesis of IL-17 or whether the effects of IL-15 in altering
the functions of Th17 population are indirect is still open.
Anyway, a recent article of Harris provided primary evidence
that IL-15 promotes Th17 and Th1 responses by skewing
monocytes into IL15-DCs. In fact, this author showed that (1)
IL15-DCs (DCs generated from monocytes using granulo-
cyte/macrophage colony stimulating factor with IL-15) pro-
duced high levels of IL-1b and IL-15 in response to TLR4
stimulation; (2) IL15-DCs stimulated with TLR agonists
secreted significantly higher concentrations of the Th17-
promoting factors, IL-1b, IL-6, IL-23, and CCL20, and lower
levels of the Th1 cytokine, IL-12; (3) IL15-DCs primed with
TLR3 or TLR4 agonists triggered Th17 (IL-17, IL-22, and/or
IFN-g) and Th1 (IFN-g) responses; and (4) secretion of IL-17
and IFN-g required contact with TLR-primed IL15-DCs (Harris
2011). Moreover, Lee and others (2010) evidenced that (1) hu-
man Th17 cell differentiation is regulated via differential ex-
pression of IL-1RI, which is controlled by IL-7 and IL-15; (2) the
differential expression of IL-1RI on human CD4+ T cells con-
fers distinct capacities in producing IL-17, and such cytokine
receptor expression is dynamically regulated via T-cell receptor
triggering and cytokines, including IL-7, IL-15, and TGF-b.
In our opinion, IL-17 secretion from CD4+ mononuclear
cells in the peripheral blood could be partially restored while
beginning a successful antiretroviral treatment and control-
ling HIV viral replication. Although the clinical characteris-
tics of our selected population may have influenced the
response to IL-15 stimulation in vitro, we noticed that the IL-
17 secretion from the CD4+ mononuclear cells of patients
with virological failure was significantly lower than in HIV-
infected patients who were successfully treated and healthy
donors. We did not observe any significant difference in
IL-17 secretion from CD4+ mononuclear cells of healthy
donors and HIV-infected patients with undetectable VL,
although IL-17 production was lower in the latter. HIV-1
infection can cause a multifaceted alteration of Th17 cells,
directly through the infection of activated CD4+ CCR5 +
and CCR6 + T cells, which represent a large percentage of
IL17-producing T cells (El Hed and others 2010). In addition,
HIV-induced systemic immune activation indirectly creates
an immunological imbalance, which results in polarization
toward other T-helper subsets (El Hed and Unutmaz 2010).
Recent studies support our hypothesis, as the complete
suppression of HIV viremia in HIV-infected children in-
duced an increased IL-17 production (Ndhlovu and others
2008). Moreover, partial but significant repopulation of IL-
17-producing cells in the sigmoid mucosa of HIV-infected
patients has been shown after a long-term anti-retroviral
treatment (Chege and others 2011).
Interestingly, a significant difference in IL-17 secretion
was found between the CD4 + mononuclear cells of HIV-
infected patients who were cART-naı¨ve with detectable VL
when compared with HIV-infected patients with detectable
HIV viremia failing the cART. One important difference
between these two groups of individuals was the higher
number of CD4 + T-cells in HIV-infected patients who were
naı¨ve to cART than the HIV-positive subjects with cART
failure. In addition, in our opinion, the preserved func-
tionality and plasticity of CD4 + T lymphocytes of the naı¨ve
subjects could have prompted an adequate response to the
in vitro stimulation with IL-15. This finding is in line with
recently published data showing the persistence of Th17
population in long-term-non-progressors HIV-infected pa-
tients in the peripheral blood and in the gut mucosa (Chege
and others 2011; Ciccone and others 2011; Salgado and
others 2011). The preservation of this subset of effector T
lymphocytes may reflect the lower level of immune acti-
vation and disease progression in this population of HIV-
infected patients.
Finally, the impaired in vivo levels of both IL-15 and IL-17
(measured in plasma samples) from the HIV subjects dem-
onstrate that the levels of these cytokines are compromised
in individuals with HIV infection; these data represent a
further support for the idea that there is a real correlation
between upregulation of IL-17 production by IL-15. More-
over the observation that the percentage of Th17 cells posi-
tively correlated with IL-17 levels evidences the fact that the
reduction in IL-17 production is simply parallel to the re-
duction in Th17 cells (Fig. 3).
Our results in plasma samples are in some way contra-
dictory compared with those obtained in vitro; however, the
fact that apparently higher levels of IL-15 induce in vivo
lower levels of IL-17 may be attributable to factors currently
not known that may reduce the effectiveness of IL-15 in
patients with non-suppressed VL. In fact, it is possible that,
in vivo, higher levels of IL-15 are required to obtain a corre-
sponding increase of IL-17 in viremic patients. At the mo-
ment, in every case, the interpretation of the data is purely
speculative, as the way in which the IL-15 modulates the
function of Th17 and the synthesis of IL-17 remains an open
question.
There are some limitations in our study that need to be
considered. First, our findings need to be confirmed in large
Table 1. Plasma Interleukin-15 and Interleukin-17
Levels Measured In Vivo and Fraction
of Th17 Cells Present Among CD4+ T Cells
of Subjects Enrolled
Patient Group
Plasma
IL-15
levels
(pg/mL)
Plasma
IL-17
levels
(pg/mL)
% Th17
cells to
total
CD4+ cells
Patient 1 cART success 2.99 24.4 3.7
Patient 2 cART success 7.000 28.3 4.0
Patient 3 cART success 9.292 29.7 4.4
Patient 4 cART success 3.042 24.8 3.3
Patient 5 cART success 5.958 27.2 4.1
Patient 6 cART failure 13.042 16.2 1.2
Patient 7 cART failure 7.208 15.8 1.6
Patient 8 cART failure 9.917 15.9 1.4
Patient 9 cART failure 7.417 16.4 2.2
Patient 10 cART failure 12.09 16.3 1.6
Patient 11 Naive for cART 9.220 19.3 2.7
Patient 12 Naive for cART 6.333 19.1 2.8
Patient 13 Naive for cART 8.667 20.7 3.1
Patient 14 Naive for cART 5.470 21.2 3.1
Patient 15 Naive for cART 4.710 18.1 2.2
Patient 16 Healthy control 2.99 31.1 5.3
Patient 17 Healthy control 2.99 30.9 5.7
Patient 18 Healthy control 2.99 32.1 6.1
Patient 19 Healthy control 6.167 30.4 5.4
Patient 20 Healthy control 2.99 31.7 6.2
IL, interleukin; cART, combined antiretroviral therapy.
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cohort studies, given the small sample of the population
studied. Second, a prospective study on the possible recovery
of IL-17-producing T cells after the introduction of cART may
provide further information. In addition, it is now known
that several different cell types, including the NK T cells, are
capable of producing IL-17. We did not evaluate the effect of
in vitro IL-15 stimulation on freshly isolated CD4+ T cells,
NK T cells, and also Th17 isolated from the gut mucosa,
which represent an important reservoir of these effector cells.
In fact, HIV-1 infection induces the depletion of Th17 in the
peripheral blood as well as in the gut mucosa (Cecchinato
and others 2008; Prendergast and others 2010). Moreover, the
preservation of IL-17-producing T lymphocytes in the gut
mucosa is associated with a slower progression of the disease
(Ciccone and others 2011). Therefore, it would be interesting
to study the effect of in vitro IL-15 stimulation on the different
cell types in a different immunological environment in HIV-
infected patients. Finally, although recent studies have shown
a controversial role of IL-15 during acute HIV and simian
immunodeficiency virus infections, its effect during the
chronic phase of HIV infection is still under observation. The
ability of IL-15 to expand different CD4+ T-cell subpopula-
tions in the animal model and the possibility to direct the NK
cell response in vitro against HIV-infected cells emphasizes
the importance of continuing the study of this cytokine.
Conclusions
In summary, we show that IL-15 can induce the secretion
of IL-17 from human CD4+ mononuclear cells of healthy
controls and HIV-infected patients. We demonstrated that
the plasma HIV-1 viremia could influence IL17 secretion.
These findings support the hypothesis that a successful
suppression of HIV-1 viral replication below the detectable
level could allow a partial restoration of Th17 cells. Thus, the
relationship between IL-15 and Th17 and their role in the
progression of HIV-1 infection needs further evaluation.
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